The Europe antifungal drugs market is expected to flourish at a CAGR of 3.23% over the forecast period of 2018-2026. The emerging pipeline of new and developing antifungal drugs is likely to present this market with amazing growth opportunities. The regions analyzed in the Europe antifungal agents market are UK, France, Germany, Spain, Italy, Scandinavia, Austria, Benelux, and rest of Europe.

EUROPE ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026

Europe Antifungal Agents Market by Drug Types (Echinocandins, Azoles, Polyenes, Allylamines & Others) by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) by Applications (Topical Antifungal Drugs, Oral Drugs) by Geography

Request free sample

The Europe antifungal drugs market is expected to flourish at a CAGR of 3.23% over the forecast period of 2018-2026. The emerging pipeline of new and developing antifungal drugs is likely to present this market with amazing growth opportunities.

The regions analyzed in the Europe antifungal agents market are UK, France, Germany, Spain, Italy, Scandinavia, Austria, Benelux, and rest of Europe. Presently, the German antifungal agents market accounts for the highest revenue share in this region. The country provides state of the art facilities in the medical sector. Also, the 2001 German Protection Against Infection Act has been a huge booster for the Europe antifungal agents market. In this report, the overall antifungal agents market is segmented on the basis of types, applications, therapeutic indications and drug types.

The major players operating in the antifungal drugs market are GlaxoSmithKline, Vertex Pharmaceuticals, Gilead, Arbor Pharmaceuticals Inc., Bayer Healthcare, Abbott Laboratories, Astellas Pharma Inc., Baxter, Sanofi- Aventis, Johnson & Johnson, Teva Pharmaceuticals, Kramer Laboratories, Merck Co, Novartis, and Pfizer

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
        • ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • POOR HYGIENE HABITS
        • DEVELOPMENT OF DRUG RESISTANCE
      • MARKET RESTRAINTS
        • GROWING AGING POPULATION IN SOME REGIONS
        • ALTERNATE TREATMENT OPTIONS
        • REGULATORY ATMOSPHERE
      • MARKET OPPORTUNITIES
        • EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
        • INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
      • MARKET CHALLENGES
        • GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
        • SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
        • RESISTANCE TO DRUGS
        • RAPIDLY CHANGING TECHNOLOGY
    1. MARKET SEGMENTATION
      • MARKET BY DRUG TYPES 2018-2026
        • SYSTEMIC AZOLES
        • TOPICAL AZOLES
        • SYSTEMIC POLYENES
        • TOPICAL POLYENES
        • SYSTEMIC ECHINOCANDINS
        • SYSTEMIC ANTIMETABOLICS
        • OTHER SYSTEMIC
        • OTHER TOPICAL
        • OTHER DRUGS TYPES
      • MARKET BY THERAPEUTIC INDICATIONS 2018-2026
        • ASPERGILLOSIS MARKET
        • DERMATOPHYTOSIS MARKET
        • CANDIDIASIS MARKET
        • OTHER THERAPEUTIC INDICATION MARKET
      • MARKET BY APPLICATIONS 2018-2026
        • TOPICAL ANTIFUNGAL AGENTS MARKET
        • ORAL DRUGS MARKET
      • MARKET BY TYPES 2018-2026
        • PRESCRIPTION
        • OVER THE COUNTER (OTC)
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
        • BARGAINING POWER OF BUYER
        • BARGAINING POWER OF SUPPLIER
        • INTENSITY OF COMPETITIVE RIVALRY
      • KEY BUYING CRITERIA
      • VALUE CHAIN ANALYSIS
        • MANUFACTURERS
        • DISTRIBUTORS
        • RETAILERS
        • END-USERS
      • REGULATORY FRAMEWORK
        • REGULATION IN EUROPE
      • OPPORTUNITY MATRIX
    2. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • UNITED KINGDOM (UK)
        • FRANCE
        • GERMANY
        • SPAIN
        • ITALY
        • BENELUX
        • SCANDINAVIA
        • AUSTRIA
        • REST OF EUROPE
    1. COMPANY PROFILES
      • COMPETITIVE LANDSCAPE
        • MARKET SHARE ANALYSIS
      • ABBOTT LABORATORIES.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ARBOR PHARMACEUTICALS, INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BAXTER
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ASTELLAS PHARMA INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BAYER HEALTHCARE
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • TEVA PHARMACEUTICALS
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • GILEAD
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • GLAXOSMITHKLINE
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • JOHNSON & JOHNSON
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • KRAMER LABORATORIES
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
      • MERCK & CO.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • NOVARTIS
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PFIZER
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI-AVENTIS
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE
      • VERTEX PHARMACEUTICALS
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVE

     

    TABLE LIST

    TABLE  1      EUROPE ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)

    TABLE  2      SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION

    TABLE  3      EUROPE ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)

    TABLE  4      DRUG USES OF TRIAZOLES

    TABLE  5      EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC  AZOLES 2018-2026 ($ MILLION)

    TABLE  6      EUROPE ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)

    TABLE  7      EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)

    TABLE  8      EUROPE ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)

    TABLE  9      EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)

    TABLE  10    EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)

    TABLE  11    EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)

    TABLE  12    EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)

    TABLE  13    EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)

    TABLE  14    EUROPE ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)

    TABLE  15    EUROPE ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)

    TABLE  16    SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES

    TABLE  17    EUROPE ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)

    TABLE  18    SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS

    TABLE  19    EUROPE ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)

    TABLE  20    EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)

    TABLE  21    EUROPE ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)

    TABLE  22    PROS AND CONS OF TOPICAL MEDICATIONS

    TABLE  23    ANTIFUNGAL POWDERS AND IT’S EFFECT

    TABLE  24    ANTIFUNGAL OINTMENT AND IT’S EFFECT

    TABLE  25    ANTIFUNGAL PASTES AND IT’S EFFECT

    TABLE  26    EUROPE ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)

    TABLE  27    COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS

    TABLE  28    EUROPE ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)

    TABLE  29    EUROPE ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)

    TABLE  30    EUROPE ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)

    TABLE  31    EUROPE ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)

    TABLE  32    EUROPE ANTIFUNGAL AGENTS MARKET BY COUNTRIES 2018-2026( $ MILLION)

    TABLE  33    TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2016

    FIGURES LIST

    FIGURE  1    EUROPE ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)

    FIGURE  2    TOPICAL ANTIFUNGAL AGENTS TYPES

    FIGURE  3    PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET

    FIGURE  4    VALUE CHAIN OF ANTIDEPRESSANT DRUGS

    FIGURE  5    THE UNITED KINGDOM ANTIFUNGAL AGENTS MARKET 2018-2026($MILLION)

    FIGURE  6    INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2017(%)

    FIGURE  7    FRANCE ANTI-FUNGAL AGENTS MARKET 2018-2026($ MILLION)

    FIGURE  8    GERMANY ANTI-FUNGAL AGENTS MARKET 2018-2026($ MILLION)

    FIGURE  9    SPAIN ANTI-FUNGAL MARKET 2018-2026($ MILLION)

    FIGURE  10  ITALY ANTI-FUNGAL MARKET 2018-2026($ MILLION)

    FIGURE  11  BENELUX ANTI-FUNGAL MARKET 2018-2026($ MILLION)

    FIGURE  12  SCANDINAVIA  ANTI-FUNGAL MARKET 2018-2026($ MILLION)

    FIGURE  13  AUSTRIA  ANTI-FUNGAL MARKET 2018-2026($ MILLION)

    FIGURE  14  REST OF EUROPE ANTI-FUNGAL MARKET 2018-2026($ MILLION)

    FIGURE  15  ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS  2017 (%)

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • UNITED KINGDOM (UK)
        • FRANCE
        • GERMANY
        • SPAIN
        • ITALY
        • BENELUX
        • SCANDINAVIA
        • AUSTRIA
        • REST OF EUROPE
    1. MARKET SEGMENTATION
      • MARKET BY DRUG TYPES 2018-2026
        • SYSTEMIC AZOLES
        • TOPICAL AZOLES
        • SYSTEMIC POLYENES
        • TOPICAL POLYENES
        • SYSTEMIC ECHINOCANDINS
        • SYSTEMIC ANTIMETABOLICS
        • OTHER SYSTEMIC
        • OTHER TOPICAL
        • OTHER DRUGS TYPES
      • MARKET BY THERAPEUTIC INDICATIONS 2018-2026
        • ASPERGILLOSIS MARKET
        • DERMATOPHYTOSIS MARKET
        • CANDIDIASIS MARKET
        • OTHER THERAPEUTIC INDICATION MARKET
      • MARKET BY APPLICATIONS 2018-2026
        • TOPICAL ANTIFUNGAL AGENTS MARKET
        • ORAL DRUGS MARKET
      • MARKET BY TYPES 2018-2026
        • PRESCRIPTION
        • OVER THE COUNTER (OTC)

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type